Literature DB >> 34128116

EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma.

Antic Tatjana1, Melissa Y Tjota2, Peter H O'Donnell3, Scott E Eggener4, Piyush K Agarwal4, Rishikesh Haridas2, Jeremy Segal2, Peng Wang2.   

Abstract

A subset of renal cell carcinomas harbor gene fusions, and we report the first case of an EZR-ROS1 fusion in renal cell carcinoma. A 47-year-old female presented with hematuria and a mass involving the renal pelvis. Renal biopsy revealed a tumor with solid and tubular architecture that was diffusely positive for PAX8, CK7, and vimentin; retained expression of INI1; focally positive for P504S; and negative for GATA3 and TFE3. Partial nephrectomy was performed, and histologically, the tumor had solid and tubular architecture with mucin-like content within tubules. The nuclei corresponded to WHO/ISUP grade 2 and 3. The morphology was neither specific nor diagnostic, and a final diagnosis of unclassified renal cell carcinoma with solid and tubular architecture was rendered. Molecular sequencing revealed an EZR-ROS1 fusion: a fusion that has never been reported in renal cell carcinoma. Recognition of this fusion is of significance if the tumor becomes metastatic as treatment with crizotinib may be considered.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  DNA sequencing; EZR-ROS1 fusion; Kidney; RNA sequencing; Renal mass

Mesh:

Substances:

Year:  2021        PMID: 34128116     DOI: 10.1007/s00428-021-03138-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  13 in total

1.  Translocation (X;1)(p11.2;q21). A subtype of renal adenocarcinomas.

Authors:  A M Meloni; A A Sandberg; J E Pontes; R M Dobbs
Journal:  Cancer Genet Cytogenet       Date:  1992-10-15

2.  Clinicopathologic and Molecular Analysis of the TFEB Fusion Variant Reveals New Members of TFEB Translocation Renal Cell Carcinomas (RCCs): Expanding the Genomic Spectrum.

Authors:  Qiu-Yuan Xia; Xiao-Tong Wang; Ru Fang; Zhe Wang; Ming Zhao; Hong Chen; Ni Chen; Xiao-Dong Teng; Xuan Wang; Xue Wei; Sheng-Bing Ye; Rui Li; Heng-Hui Ma; Zhen-Feng Lu; Xiao-Jun Zhou; Qiu Rao
Journal:  Am J Surg Pathol       Date:  2020-04       Impact factor: 6.394

3.  Renal neoplasia with papillary architecture involving the pelvicalyceal system.

Authors:  Sounak Gupta; John C Cheville; Belinda K Galeano; William R Sukov; Loren Herrera-Hernandez; Katelyn A Reed; Christine M Lohse; R Houston Thompson; Stephen A Boorjian; Bradley C Leibovich; Rafael E Jimenez
Journal:  Hum Pathol       Date:  2020-11-06       Impact factor: 3.466

4.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Amog Xp11 Translocation Cancers.

Authors:  Kristyna Pivovarcikova; Petr Grossmann; Reza Alaghehbandan; Maris Sperga; Michal Michal; Ondrej Hes
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

5.  Melanotic Translocation Renal Cell Carcinoma With a Novel ARID1B-TFE3 Gene Fusion.

Authors:  Tatjana Antic; Jerome B Taxy; Mir Alikhan; Jeremy Segal
Journal:  Am J Surg Pathol       Date:  2017-11       Impact factor: 6.394

6.  Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.

Authors:  Marion Classe; Gabriel G Malouf; Xiaoping Su; Hui Yao; Erika J Thompson; Denaha J Doss; Valérie Grégoire; Julien Lenobin; Jean-Christophe Fantoni; Hélène Sudour-Bonnange; David Khayat; Sébastien Aubert; Nizar M Tannir; Xavier Leroy
Journal:  Histopathology       Date:  2017-03-21       Impact factor: 5.087

7.  Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays.

Authors:  Sabah Kadri; Bradley C Long; Ibro Mujacic; Chao J Zhen; Michelle N Wurst; Shruti Sharma; Nadia McDonald; Nifang Niu; Sonia Benhamed; Jigyasa H Tuteja; Tanguy Y Seiwert; Kevin P White; Megan E McNerney; Carrie Fitzpatrick; Y Lynn Wang; Larissa V Furtado; Jeremy P Segal
Journal:  J Mol Diagn       Date:  2016-11-09       Impact factor: 5.568

Review 8.  2004 WHO classification of the renal tumors of the adults.

Authors:  Antonio Lopez-Beltran; Marina Scarpelli; Rodolfo Montironi; Ziya Kirkali
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

Review 9.  Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.

Authors:  Leow Pay Chin; Ross A Soo; Richie Soong; Sai-Hong I Ou
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

Review 10.  WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies.

Authors:  Anne Y Warren; David Harrison
Journal:  World J Urol       Date:  2018-08-19       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.